Taking care of human health and improving the quality of lifeCommitted to becoming a distinctive international pharmaceutical company, focusing on health care.Stock code: 002923As a modernized science and technology-based pharmaceutical enterprise integrating drug research and development, production and sales, Zhuhai Rundu Pharmaceutical Co., Ltd. (hereinafter referred to as Rundu), founded in 1999, is located in Jinwan District, Zhuhai City, Guangdong Province, PRC. On January 05, 2018, Rundu was listed on the Shenzhen Stock Exchange (stock abbreviation: Rundu Pharma; stock code: 002923), with a registered capital of 334 million yuan. Rundu now has more than 2,000 full-time employees.
The main business of Rundu is the research and development, production and sales of chemical pharmaceutical preparations, APIs and pharmaceutical intermediates, and the scope of the products covers a wide range of fields such as peptic ulcer, hypertension, surgical anesthesia, antipyretic, anti-infective, diabetes, etc. Rundu has a perfect quality management system and has set up a pharmaceutical production and manufacturing center in strict accordance with the national GMP requirements. The existing product lines (covering APIs, tablets, capsules, preparation intermediates (micro-pills), etc.) have passed the new version of the national GMP certification, and some of the featured API products have passed the inspections of the World Health Organization (WHO), the CEP approved by EDQM, and MF approved and inspected by Japan PMDA, and some of them have passed the on-site inspection of the U.S. FDA.
Rundu is a National High-tech Enterprise, National Technology Center, National Green Factory, National Ph.D Research Station, National Intellectual Property Advantageous Enterprise, Guangdong Provincial Technology Center, Guangdong Engineering Technology Research Center, and Guangdong Innovative Enterprise, with strong technical innovation ability and solid scientific research foundation. Up to now, Rundu has 52 pharmaceutical registration certificates for preparations (including intermediates), 27 API products, 10 new drug certificates, 4 national key new products, and 183 patents, including 94 invention patents.
Rundu adhered to the development concept of ‘Focus on Achieving Excellence, Technology Carries the Future’, and actively developed the development of original innovative drugs and the technological upgrading of multiple varieties of drugs while continuing to maintain its leading position in the development of new dosage forms of unique drugs (pellet capsule preparation technology, pellet tablet preparation technology, etc.) and enteric-coated and sustained-release preparations. Rundu is moving toward the gradual promotion of the industrial upgrading strategy of vertical integration from APIs to preparations, carrying out diversified R&D models, strengthening cooperation with domestic and foreign first-class R&D institutions, developing a series of high-class preparation products, promoting the development of the company's international trade, gradually realizing the company's internationalization strategy, and striving to become a leading enterprise in the domestic production of pellet preparations, antihypertensive sartan drugs, anti-peptic ulcer proton pump inhibitors and other characteristic products.
Stock code002923
